GlassScriptPhysician profile
Mohamed El-Naghy
NPI 1396159919
$744.59
in general payments reported to CMS, 2019-2025
10 companies · $47.27 in 2025
The $47.27 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13.37 · 2021: $11.92 · 2023: $134 · 2024: $538 · 2025: $47.27.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $400 · Food and Beverage: $319.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $400.00 |
| Food and Beverage | $319.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $400.00 | 2024 | Imfinzi |
| Glaxosmithkline, LLC. | $72.45 | 2023-2025 | Blenrep, Ojjaara, Jemperli |
| Pfizer INC. | $52.53 | 2024 | |
| Janssen Biotech, INC. | $46.23 | 2023 | Erleada, Abiraterone Acetate |
| Novartis Pharmaceuticals Corporation | $41.31 | 2023-2024 | |
| Abbvie INC. | $34.66 | 2024 | |
| Gilead Sciences, INC. | $30.71 | 2021-2023 | |
| Daiichi Sankyo INC. | $28.77 | 2024 | Enhertu |
| E.R. Squibb & Sons, L.L.C. | $24.56 | 2023 | Reblozyl |
| Eisai INC. | $13.37 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohamed El-Naghy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.